Nationwide Fund Advisors’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-36,967
| Closed | -$414K | – | 3045 |
|
|
2017
Q3 | $414K | Sell |
36,967
-992
| -3% | -$10.9K | ﹤0.01% | 2275 |
|
|
2017
Q2 | $418K | Hold |
37,959
| – | – | ﹤0.01% | 2269 |
|
|
2017
Q1 | $372K | Sell |
37,959
-1,965
| -5% | -$19.6K | ﹤0.01% | 2311 |
|
|
2016
Q4 | $431K | Sell |
39,924
-1,338
| -3% | -$13.4K | ﹤0.01% | 2251 |
|
|
2016
Q3 | $423K | Hold |
41,262
| – | – | ﹤0.01% | 2260 |
|
|
2016
Q2 | $539K | Buy |
41,262
+708
| +2% | +$9.28K | ﹤0.01% | 2116 |
|
|
2016
Q1 | $446K | Sell |
40,554
-2,327
| -5% | -$20.7K | ﹤0.01% | 2156 |
|
|
2015
Q4 | $395K | Buy |
42,881
+804
| +2% | +$6.73K | ﹤0.01% | 2236 |
|
|
2015
Q3 | $292K | Hold |
42,077
| – | – | ﹤0.01% | 2382 |
|
|
2015
Q2 | $413K | Sell |
42,077
-5,657
| -12% | -$51.5K | ﹤0.01% | 2352 |
|
|
2015
Q1 | $423K | Sell |
47,734
-1,378
| -3% | -$11K | ﹤0.01% | 2322 |
|
|
2014
Q4 | $430K | Sell |
49,112
-923
| -2% | -$7.47K | ﹤0.01% | 2273 |
|
|
2014
Q3 | $345K | Hold |
50,035
| – | – | ﹤0.01% | 2425 |
|
|
2014
Q2 | $263K | Sell |
50,035
-1,872
| -4% | -$9.11K | ﹤0.01% | 2609 |
|
|
2014
Q1 | $236K | Hold |
51,907
| – | – | ﹤0.01% | 2418 |
|
|
2013
Q4 | $262K | Sell |
51,907
-691
| -1% | -$3.33K | ﹤0.01% | 2560 |
|
|
2013
Q3 | $267K | Buy |
52,598
+685
| +1% | +$3.81K | ﹤0.01% | 2524 |
|
|
2013
Q2 | $257K | Buy |
+51,913
| New | +$247K | ﹤0.01% | 2371 |
|
Nationwide Fund Advisors's SCLN Position: Q4 2017 in Review
Nationwide Fund Advisors sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 36,967 shares — an estimated $414K sold.
Nationwide Fund Advisors first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $539K in Q2 2016. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Nationwide Fund Advisors reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Nationwide Fund Advisors sold 36,967 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $414K.
- Nationwide Fund Advisors first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- Nationwide Fund Advisors's Sciclone Pharmaceuticals Inc position peaked at $539K in Q2 2016.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.